Third-, Fourth-line Sorafenib Therapy May Not Boost Overall Survival

Share this content:
Third- and fourth-line sorafenib therapy does not significantly increase overall survival in patients with relapsed/refractory non –small cell lung cancer.
Third- and fourth-line sorafenib therapy does not significantly increase overall survival in patients with relapsed/refractory non –small cell lung cancer.

Third- and fourth-line sorafenib therapy does not significantly increase overall survival in patients with relapsed/refractory non–small cell lung cancer (NSCLC), according to a recent study published in the Journal of Thoracic Oncology.1

Luis Paz-Ares, MD, PhD, of the Instituto de Investigaciones Biomédicas de Sevilla in Spain conducted the MISSION trial, a phase 3, multinational, double-blind, placebo-controlled study to examine patients with advanced relapsed/refractory NSCLC following 2 or 3 prior regimens who received either sorafenib or placebo.

Primary endpoint was overall survival, while secondary endpoints included progression-free survival and time-to-progression.

RELATED: Nedaplatin Plus Docetaxel May Be New Treatment for Squamous Cell Lung Cancer

They found that median overall survival was similar between the 2 groups, while median progression-free survival and time-to-progression were significantly greater in the sorafenib group.

In 89 patients who were observed for EGFR mutations, overall survival was significantly higher in sorafenib compared to placebo. While progression-free survival was significantly longer with sorafenib in patients with either wild-type or mutated KRAS, overall survival was similar.

Reference

  1. Paz-Ares L, Hirsh V, Zhang L, et al. MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens [published online ahead of print November 6, 2015]. J of Thoracic Oncol.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs